Press Releases

The 2014 OTC Guide supplement issue, website, and mobile app, touted on the TODAY show, announce the most recommended OTC products in more than 150 categories. The collective recommendations of thousands of pharmacists were revealed on...

Astellas today announced progress on the Company's efforts to reshape its research framework at its R&D meeting held in Tokyo on July 10. The meeting provided an opportunity for Astellas to present a comprehensive overview of its late-stage clinical...

Obese patients who underwent surgery or took medications to lose weight were more satisfied with their results than those who made lifestyle changes. Nearly 60% of obese patients are not taking any action to lose weight, according to the results...

Offers new treatment option for genotype 1 HCV patients in Japan who are interferon-ineligible/intolerant, or did not previously respond to treatment Japanese HCV patients in urgent need of care now have opportunity for cure, including older patients and those...

genOway guarantees freedom to operate (FTO) and offers important gains in conditional knockout development time for industry scientists Lyon, France, July 2, 2014 - genOway (Alternext-NYSE Euronext: ALGEN; ISIN: FR0004053510), the biotechnology company dedicated to the development of genetically modified...

Cancer immunotherapy research departments need to break their obsession with the latest flavour of the month - checkpoint inhibitors - and concentrate more on combining checkpoint inhibitors with APC activators, thinks Dr. Frederic Triebel, the founder of the French...

Proveblue(R) is the methylthioninium chloride or Methylene Blue active substance patented by Provepharm, compliant with current European Pharmacopeia standards Provepharm, a French company specialized in the development of pharmaceutical applications, and Dr Franz Kohler Chemie (DFKC),...